Coleman D.
Martin
a,
Andrew T.
Bender
b,
Benjamin P.
Sullivan
b,
Lorraine
Lillis
c,
David S.
Boyle
c and
Jonathan D.
Posner
*abd
aDepartment of Chemical Engineering, University of Washington, Seattle, Washington, USA
bDepartment of Mechanical Engineering, University of Washington, Seattle, Washington, USA
cPATH, Seattle, Washington, USA
dDepartment of Family Medicine, University of Washington, Seattle, Washington, USA
First published on 12th January 2024
Nucleic acid amplification tests for the detection of SARS-CoV-2 have been an important testing mechanism for the COVID-19 pandemic. While these traditional nucleic acid diagnostic methods are highly sensitive and selective, they are not suited to home or clinic-based uses. Comparatively, rapid antigen tests are cost-effective and user friendly but lack in sensitivity and specificity. Here we report on the development of a one-pot, duplexed reverse transcriptase recombinase polymerase amplification SARS-CoV-2 assay with MS2 bacteriophage as a full process control. Detection is carried out with either real-time fluorescence or lateral flow readout with an analytical sensitivity of 50 copies per reaction. Unlike previously published assays, the RNA-based MS2 bacteriophage control reports on successful operation of lysis, reverse transcription, and amplification. This SARS-CoV-2 assay features highly sensitive detection, visual readout through an LFA strip, results in less than 25 minutes, minimal instrumentation, and a useful process internal control to rule out false negative test results.
Reverse transcription PCR (RT-PCR) is the gold standard for SARS-CoV-2 molecular testing due to its high sensitivity and specificity, which is crucial for accurate detection during the early phase of infection when viral titers are low.3 Scaled RT-PCR testing is primarily limited to central laboratories due to the need for specialized equipment for nucleic acid extraction, assay preparation, thermocycling, and target detection. These high-resource requirements result in delays from sampling to answer which delays clinical interventions that can prevent disease progression or reduce community transmission.4 Rapid lateral flow assay (LFA) antigen testing is the most widely used SARS-CoV-2 testing because of its low cost, ease of use, speed, and over-the-counter availability for use at home.5 LFAs have poorer clinical accuracy compared to nucleic acid-based tests and have poorer limits of detection, so there are inherent risks that early infection may not be detected when low viral loads are typically present.6–10
Commercial point-of-care (POC) RT-PCR based diagnostics (Abbott ID Now, Cepheid GeneXpert Xpress, Roche cobas Liat, etc.) have been developed and received US FDA emergency use authorization to increase the accessibility of molecular tests with high clinical diagnostic accuracy. These cartridge-based platforms generally have an assay time greater than 30 minutes (ref. 11 and 12) and use desktop readers that automate fluidic handling, amplification, detection, and assay result interpretation. With the goal of increasing accessibility to NAAT testing, government initiatives to accelerate product development (e.g., NIH RADx program) led to several single-use disposable and lower cost NAATs that were specifically targeted for community-based use (physician's office) or home/self-testing (e.g., Lucira CheckIt, Cue COVID-19, Aptitude Metrix, etc.).2,13–15 These commercially available tests use fluorescence or electrochemical detection and require onboard electronics to sense, analyze, and report test results.
Isothermal NAATs with LFA readout can offer the high diagnostic accuracy of RT-PCR and the low-cost and ease of use of antigen-based LFAs. Recombinase polymerase amplification (RPA) is an attractive isothermal amplification method due to its speed (<15 min), accuracy, and low incubation temperature (∼40 °C). Early in the pandemic, multiple SARS-CoV-2 RPA assays were published that targeted either the nucleocapsid (N),16–19 spike (S),18,20 RNA dependent RNA polymerase (RdRp),21 or open reading frame 1 (ORF1ab)20,22 genes with analytical sensitivities as low as 10 RNA copies per reaction while leveraging fluorescent output and/or lateral flow detection. Several RPA assays using LFA detection have incorporated duplexing of multiple SARS targets, RNase P for sampling validation, or simultaneous detection of SARS-CoV-2 and influenza virus targets.23–27 While targeting the human RNase P gene is useful for confirming sampling integrity from a human source, it is not a full process internal control as it is DNA-based and fails to report on potential RNA degradation and reverse transcription.
In this work, we report on the development of a one-pot, duplexed RT-RPA SARS-CoV-2 assay with an MS2 bacteriophage as a full process control. The duplexed assay can detect amplicons with real-time fluorescence or lateral flow readout using commercially available RPA reagent kits that include an exonuclease for molecular probe cleavage (TwistAmp exo). The MS2 bacteriophage process control reports on successful operation of lysis, reverse transcription, and amplification. The assay has a SARS-CoV-2 RNA sensitivity of 25 copies per reaction when using fluorescence readout and 50 copies per reaction with lateral flow detection. We also demonstrate the ability of the current assay to detect the SARS-CoV-2 Delta and Omicron variants. To our knowledge, this is the first report of a duplexed SARS-CoV-2 lateral flow detection assay to incorporate a full process internal control that reports on lysis, reverse transcription, and amplification. This is also the first reported usage of TwistAmp exo RPA kits for both fluorescence and lateral flow readout, opening the potential for multiple assay readout options with a single reagent format given the resources at the point of testing.
The RT-RPA assay was designed to target the nucleocapsid (N) gene based on the SARS-CoV-2 reference genome (GenBank NC_045512). The assay uses an internally quenched fluorophore probe that was designed using computational and manual methods. Candidate probe sequences were generated using RPA assay design software PrimedRPA.29 The final probe sequence for the assay was selected based on the location of available thymine residues for an internally quenched fluorophore, genome conservation through alignment of other available sequences, and low degree of homology through BLAST alignment of other respiratory viruses. Twelve primer pairs were then designed around this probe sequence using PrimedRPA29 and screened using RT-RPA with fluorescence readout. The best primer candidates were chosen based on time to threshold and slope of the exponential amplification curve. The primers were redesigned with single base-pair shifts and length changes for second round screening, following the TwistDx assay design manual. The primers were again screened for optimal time to threshold. In total, 21 different primer pairs were evaluated with the top performing pair being selected for subsequent experiments (Fig. S2†). The resulting primer pair (Table 1) displayed the shortest time to threshold and the steepest exponential amplification slope. MS2 primers and probe are provided in the ESI† (Table S1).30
Oligo | Sequence |
---|---|
SARS-CoV-2 forward | AAGCCTCTTCTCGTTCCTCATCACGTAG |
SARS-CoV-2 reverse | GTTGGCCTTTACCAGACATTTTGCTCTCA |
SARS-CoV-2 reverse lateral flow | GTTGGCCTTTACCAGACATTTTGCTCTCA-[biotin] |
SARS-CoV-2 probe | GGCGGTGATGCTGCTCTTGCTTTGCTGC-[T(FAM)]-G-dSpacer-[T(BHQ1)]-TGACAGATTGAACCAGC-Spacer C3 |
Sequence-specific amplicon detection of SARS-CoV-2 and MS2 via RT-RPA employs enzymatically-cleaved homologous probes. These probes have 48 base pairs, use a FAM or ROX fluorophore, a tetrahydrofuran (THF) residue, an internal quencher (only in fluorescence readout probe design), and a 3′ block to inhibit probe extension. The fluorescence detection mechanism for SARS-CoV-2 uses a thymine modified with a FAM fluorophore that is 5′ of a proximal THF site and a subsequent thymine modified with an internal fluorophore quencher, as detailed elsewhere.31 Fluorescence detection of MS2 follows the same methodology with the difference of a ROX fluorophore in place of the FAM fluorophore. Given sufficient sequence homology, the DNA exonuclease III (Exo) acts on the THF site, freeing the fluorophore and quencher and allowing for fluorescence. While this assay utilizes a sequence-specific probe, perfect homology across the primer and probe targeting region is not required as RPA has been shown to tolerate up to 15 mismatches, allowing for a high degree of cross variant detection.32In silico alignments displayed two total mismatches for the delta variant with a G to T mutation on the probe's first 5′ base, the other mutation occurs outside the primer or probe regions. Alignments also show 3 consecutive mismatches (GGG to AAC) in the omicron variant. These occur outside the primer and probe hybridization regions, and therefore do not impact the assay's performance.
Duplexed RT-RPA assays with fluorescence readout used the same reaction protocol as outlined above, with adjustments to include MS2 bacteriophage RNA, primers, and probe. Duplexed RT-RPA reactions for SARS-CoV-2 and MS2 included 1.08 μL of 10 μM MS2 forward primer, 1.08 μL of 10 μM MS2 reverse primer (Integrated DNA Technologies, USA), 0.19 μL of 10 μM MS2 probe labeled with a ROX fluorophore (LGC Biosearch Technologies, UK), 2 μL of 4.2 × 105 copies per μL (cps/μL) MS2 RNA (Sigma Aldrich, USA), and nuclease-free water as needed to achieve a total reaction volume of 50 μL. As outlined above, tubes were agitated immediately before placing in an Axxin T16 for incubation at 39 °C and fluorescence readout. The LED intensity setting in the FAM channel was set to 7% while the ROX LED intensity was set to 52%.
After eight minutes of run time, the LFA test strips were removed, pat dried with a Kem wipe (Kimberly-Clark, USA) and scanned with an Epson V370 photo flatbed scanner for use in code-based image analysis. The LFA images were processed by a code (Python 3.10) that calculates the line average intensity of the test line region. A positive result was determined if the line intensity of the test line exceeded the intensity threshold set by the average of all NTCs plus three standard deviations. For qualitative presentation here, the LFA were dried and digitally imaged (EOS Rebel T3, Canon) with a 60 mm macro lens.
Duplexed RT-RPA with lateral flow detection leveraged the chemistry above with the addition of MS2 RNA, primers, and probe. Duplexed reactions included 1.05 μL of 10 μM forward primer, 1.05 μL of 10 μM MS2 reverse primer labeled with digoxigenin, 0.3 μL of 10 μM MS2 probe labeled with a FAM fluorophore (Integrated DNA Technologies), 2 μL of 4.2 × 105 cps/μL MS2 RNA (Sigma Aldrich), and nuclease-free water as needed for a 50 μL total reaction volume. The duplexed assay with LFA readout was conducted in the same manner as outlined for single target detection.
We use two different RPA probe designs in the LFA assay, which are detailed in Table S1.† The first is an internally quenched probe targeting SARS-CoV-2 that is also used for fluorescence readout. The second is a probe with an unquenched 5′ terminal fluorophore label for MS2 amplicon detection as described in the TwistDx design manual and as published in past RPA assays with LFA readout.31,33,34 LFA “sandwich” immunochemistry detection on a nitrocellulose strip uses these RPA probes combined with modified primers: 5′ biotinylated SARS-CoV-2 reverse primer and 5′ digoxigenin-labeled MS2 reverse primer. LFA banding visualization is based on the binding of a dual labeled RPA product being “sandwiched” between the immobilized receptor and an anti-FAM antibody conjugated to a gold nanoparticle. The first binding domain detects the SARS-CoV-2 amplification product which is labeled via the biotinylated reverse primer and cleaved FAM probe, as illustrated in Fig. 1. The second binding domain detects the MS2 amplification product which is similarly labeled with digoxigenin and FAM. The third binding domain serves as the LFA flow control by capturing conjugated gold nanoparticles that did not bind to RPA products.
Within the duplex RT-RPA assay, the MS2 input copies and concentrations of primers and probe were optimized to retain a low LOD for SARS-CoV-2 detection, while also consistently amplifying the MS2 internal control. The SARS-CoV-2 primer and probe concentrations were conserved throughout both the mono and duplexed assays. MS2 primer and probe concentrations were determined through a systematic screening of lower MS2 oligo concentrations while maintaining SARS-CoV-2 assay performance. Concurrent with the oligo concentration, we evaluated MS2 input copies on the amplification behavior. The final concentration of MS2 RNA in the assay was determined through optimization such that the time to threshold of the MS2 amplification was less than 7 minutes and all MS2 reactions consistently amplified regardless of input copy load of SARS-CoV-2 RNA. We observed that the optimal total oligonucleotide concentration in the reaction was 1540 μM. Further increases in the oligo concentration demonstrated increased time to threshold and reduced exponential amplification slope, resulting in worse duplexed assay performance. We hypothesize that the decrease in performance is due to oligo saturation of the single stranded binding proteins and/or recombinase proteins, which inhibits the strand invasion and primer hybridization steps of RPA.
In order to implement LFA detection of RT-RPA products, we explored different probe designs and TwistAmp RPA enzyme kits for LFA detection. Many previously published RPA assays with LFA readout use the TwistAmp nfo kit and a 5′ unquenched fluorophore probe as in the TwistAmp RPA design manual.31,33,34 At the time of experimentation, the TwistAmp nfo kit was discontinued and no longer available for purchase from TwistDx Limited (now a subsidiary of Abbott Laboratories). Attempts were made to spike purchased endonuclease IV (nfo) enzyme to a TwistAmp basic kit with mild success (data not shown); however, through experimentation we found that sensitivity of the LFA assay was improved using the TwistAmp exo kits, which are typically reserved for real-time fluorescence readout. We evaluated the performance of the internally quenched fluorescence detection probe design compared to a 5′ unquenched fluorophore LFA probe design and found the detection limit to be equivalent. To demonstrate the utility of these probe designs, we carried out all LFA readout experiments using the 5′ unquenched FAM fluorophore probe design for MS2 detection and the internally quenched FAM fluorophore probe design for SARS-CoV-2 detection. We observed that employing TwistAmp exo kits and internally quenched probes enables dual readout, either through real-time fluorescence or endpoint LFA analysis. This is notable because RPA primer and probe screening is most efficiently performed using real-time fluorescence data to indicate optimal primer and probe combinations, which can then be leveraged directly for LFA readout if desired.
Using the RPA probe design, we conducted experiments to detect SARS-CoV-2 using RT-RPA paired with lateral flow readout. Fig. 3 shows representative LFA strip images and quantitative measurement of LFA line intensities (5 strip average) for SARS-CoV-2. The images show positive lines for the flow controls and SARS-CoV-2 for all concentrations down to 25 copies per reaction. The MS2 LFA line is not present, as expected, because the MS2 RNA, primers, and probe are not included in the monoplex version of the assay. The quantitative results in Fig. 3B show that the line intensity increases with increasing input copy numbers.
We repeated these lateral flow readout experiments with the duplex RT-RPA assay for SARS-CoV-2 with MS2 internal control. Fig. 4 shows representative strip images of the duplexed LFA and quantitative measurement of LFA line intensities averaged over 5 replicates. The images show a positive line for the flow control, MS2 internal control, and the SARS-CoV-2 strip regions for all concentrations down to 25 copies per reaction. We observe that the MS2 line intensity levels are greater than the SARS-CoV-2 test lines. This is likely due to the excess MS2 RNA in the reaction. The quantitative analysis shows that the SARS-CoV-2 line intensity decreases with copy number, except at 25 cps/rxn where the average line intensity and standard deviation is much greater than expected. This is due to two replicates, one where the SARS-CoV-2 test stripe intensity was much greater than three replicates and one replicate that failed to develop a line at an intensity reaching the determination cut off both visually and by the objective code method. This low line intensity replicate was retested with the same result. As observed in the fluorescence readout data in Fig. 2, high variation in RT-RPA amplification is common near the limit of detection of the assay.
Table 2 summarizes the observed LODs of the RT-RPA assay with fluorescence or LFA readout for both monoplex detection of SARS-CoV-2 and duplexed detection of SARS-CoV-2 and the MS2 internal control. We list the detection fraction of SARS-CoV-2 RNA from 250 cps/rxn to 5 cps/rxn stratified by readout method and monoplexed versus duplexed target detection. RT-RPA with fluorescence readout demonstrated lower LOD with mixed positive results at 5 cps/rxn and a limit of detection of 25 cps/rxn in both single target and duplexed assays. Monoplexed RT-RPA with LFA readout exhibited a 100% SARS-CoV-2 detection rate down to 25 cps/rxn. The duplexed LFA of variable SARS-CoV-2 target and fixed MS2 target demonstrated 100% detection rate down to 50 cps/rxn and 80% detection rate at 25 cps/rxn. Neither monoplexed nor duplexed LFA could detect any LFA banding through either visual or analytical detection at 5 cps/rxn.
Detection method | 250 cps/rxn | 100 cps/rxn | 50 cps/rxn | 25 cps/rxn | 5 cps/rxn | NTC |
---|---|---|---|---|---|---|
Singleplex RT-RPA with fluorescence | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 0/5 |
Duplex RT-RPA with fluorescence | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 0/5 |
Singleplex RT-RPA with LFA | 5/5 | 5/5 | 5/5 | 5/5 | 0/5 | 0/5 |
Duplex RT-RPA with LFA | 5/5 | 5/5 | 5/5 | 4/5 | 0/5 | 0/5 |
The duplex RT-RPA assay with LFA readout was tested with other respiratory viruses in order to assess its analytical specificity. Table 3 shows detection of SARS-CoV-2 variants Delta B.1.617.2 and Omicron B.1.1.529 and cross-reactivity screening against genomic RNA from other common respiratory viruses. The data shows that the assay has no cross-reactivity with influenza A, influenza B, human coronavirus 229E (HCoV-229E), HCoV-NL63, or HCoV-OC43. The SARS-CoV-2 Delta and Omicron variants RNA were detected in all three replicates at input copy loads of 103 cps/rxn (Fig. S6 and S7†). We did not thoroughly evaluate the LOD for these variants of concern, but we expect similar results to Table 2 which used RNA from the ancestral SARS-CoV-2 strain. In alignments of these SARS-CoV-2 variant sequences with our RPA primers and probe, we discovered no mismatches in the hybridization regions; therefore, we anticipate no significant effect on limit of detection. There are some sublineages that introduce minimal mismatches with our RPA sequences, but we do not expect significant impacts to our assay's performance due to the mismatch tolerance of RPA that has been reported previously by our research group and others.32,36
Virus | Concentration (cps/rxn) | Positive replicates |
---|---|---|
Flu A | 103 | 0/3 |
Flu B | 103 | 0/3 |
HCoV-229E | 103 | 0/3 |
HCoV-NL63 | 103 | 0/3 |
HCoV-OC43 | 103 | 0/3 |
Delta | 103 | 3/3 |
Omicron | 103 | 3/3 |
We validated the internal MS2 viral control using heat for viral lysis and sample preparation. Heat lysis has been demonstrated as an effective viral lysis technique compatible with nucleic acid amplification assays.18,37,38 We conducted a series of duplexed RT-RPA experiments with LFA readout at 103 copies per reaction (N = 3) to demonstrate efficacy of heat-based lysis and the MS2 full process internal control. Prior to RT-RPA analysis, we pre-treated intact SARS-CoV-2 virus and MS2 bacteriophage to generate four different samples: MS2 and SARS-CoV-2 both heat-lysed, only SARS-CoV-2 lysed, only MS2 lysed, and no lysing. Fig. 5 shows representative images of LFA strips for RT-RPA of pretreated samples directly added to reactions. All four conditions yielded the expected results as using lysed materials permitted successful RT-RPA and LFA detection, while unlysed materials did not amplify and therefore gave negative test results. In instances where MS2 detection fails, this indicates an invalid test result due to a failure of one or more integral steps, and retesting is required. This result could be due to RNA degradation or unsuccessful viral lysis, reverse transcription, or amplification. Failure to use a full process internal control may increase risk of false negatives and misdiagnosis, which prevents immediate clinical interventions that mitigate community spread.
This SARS-CoV-2 assay meets multiple characteristics for assay performance as set forth by the World Health Organization's COVID-19 Target Product Profile (TPP) for priority diagnostics to support response to the COVID-19 pandemic.42 The TPP lists the desirable analytical test sensitivity to be equivalent to 104 genome copies per mL. We have demonstrated a duplexed assay with an analytical sensitivity of 50 copies per reaction. The TPP further lists desirable analytical specificity as the ability to detect all SARS-CoV-2 viral strains, not reacting with interferants, and not cross reacting with other common viral diseases that present with common signs and symptoms of COVID-19 like influenza A/B. Here, we have demonstrated that the assay detects both the delta and omicron variants while not cross reacting with other human coronaviruses nor influenza A or B. For interpretation of test results, the TPP lists visual manual readout in both the acceptable and desired categories which is achieved with our lateral flow readout mechanism. We have demonstrated this assay to be rapid with lateral flow results in 28 minutes from raw sample lysis to answer. The use of RPA also has inherent benefits as the lyophilized reaction pellets have been proven to be stable outside of cold chain storage for up to 12 weeks.43
To our knowledge, this assay is the first reported duplexed SARS-CoV-2 RPA assay for lateral flow strip detection format that incorporates an internal full process internal control that reports on the successful lysis, reverse transcription, and amplification of each RNA test reaction. It is also the first reported use of the RPA TwistAmp exo kits for both fluorescence and lateral flow detection formats opening the possibility for multiple assay readout options with a single kit, albeit with slight differences in assay performance. This utility of exo-based kits for LFA also enables convenient RPA assay design and optimization as primer and probe combinations can be tested with real-time readout instead of endpoint analysis.
Footnote |
† Electronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d3sd00246b |
This journal is © The Royal Society of Chemistry 2024 |